BIO Comments On Medicare Drug Discount Agreement Announced By PhRMA, The White House And Senate Finance Committee

Main Category: Medicare / Medicaid / SCHIP
Article Date: 26 Jun 2009 - 7:00 PDT

email to a friend   printer friendly   opinions  

The following statement was issued today by the Biotechnology Industry Organization (BIO) regarding the agreement reached among the Obama administration, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Senate Finance Committee to help close the coverage gap in the Medicare prescription drug program:

"We look forward to reviewing in greater detail the agreement struck among President Obama, PhRMA and the Senate Finance Committee.

"We will examine the deal through the lens of measuring its impact on the ability of biotechnology researchers to continue to develop and produce breakthrough medicines and therapies that extend and improve the quality of life - and provide renewed hope - for patients suffering from debilitating diseases such as cancer, Parkinson's, Multiple Sclerosis and a host of rare diseases.

"We share the goal of ensuring that all Americans have access to high quality health care. We look forward to continuing our participation in the process of reforming our nation's health care system to increase access and reduce costs while promoting the continued development of new therapies and cures."

Source
BIO

• Additional
• References
• Citations